Bristol Myers Squibb has added a familiar face to an ongoing initiative to thank oncologists for the valuable time they ...
Opdivo (nivolumab) has been approved for two new classical Hodgkin lymphoma (cHL) indications in the US and the EU. The US ...
Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results